MANU:NYSEManchester Analysis
Data as of 2026-04-16 - not real-time
$17.69
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Manchester United plc trades at $17.69, comfortably above its 20‑day ($17.04) and 50‑day ($17.22) moving averages, while the 200‑day average ($16.76) also sits below the current price, indicating a technically supportive backdrop. The MACD line remains bullish (0.226 vs signal 0.108) and the RSI sits at 58.9, suggesting the stock is not yet overbought but edging toward the upper range. However, fundamentals tell a different story: revenue has slipped 4.2%, the company posted a negative profit margin (-1.38%) and a trailing EPS of -$0.07, while forward EPS is only $0.08, inflating the forward P/E to 217 versus an industry average of 19. Debt is a major concern, with $780 million in liabilities versus $44 million in cash, yielding a debt‑to‑equity ratio above 400. The DCF fair‑value estimate of $1.80 and a price‑to‑book of 11.8 further underscore the overvaluation. Volatility is elevated at 26.6% over the past 30 days, and volume trends are decreasing, hinting at waning investor interest. The market sentiment is extremely bullish (Fear‑Greed Index 88.98), yet the upside potential is largely driven by speculative catalysts such as a possible Champions League qualification, which could revive sponsorship and commercial revenues. In this context, the stock appears technically stable but fundamentally strained, with high leverage, weak cash generation, and a valuation that far exceeds earnings expectations.
Investors should therefore weigh the short‑term technical comfort against the long‑term structural risks. While a Champions League berth could provide a temporary boost, the underlying financial profile suggests limited upside and heightened downside risk if performance fails to improve.
Investors should therefore weigh the short‑term technical comfort against the long‑term structural risks. While a Champions League berth could provide a temporary boost, the underlying financial profile suggests limited upside and heightened downside risk if performance fails to improve.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Technical support from moving averages and bullish MACD
- Elevated valuation metrics (forward P/E 217, price-to-book 11.8)
- Decreasing volume indicating potential liquidity concerns
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Potential Champions League qualification driving sponsorship revenue
- Strong brand equity and high gross margin
- Technical momentum with price above key averages and bullish MACD
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Unsustainable debt load and negative free cash flow
- Persistent revenue decline and negative profit margin
- Severe overvaluation relative to earnings and DCF fair value
Key Metrics & Analysis
Financial Health
Revenue Growth-4.20%
Profit Margin-1.38%
P/E Ratio217.2
ROE-4.68%
ROA-0.09%
Debt/Equity409.14
P/B Ratio11.8
Op. Cash Flow$109.9M
Free Cash Flow$-44589752
Industry P/E19.0
Technical Analysis
TrendNeutral
RSI58.9
Support$16.16
Resistance$17.96
MA 20$17.04
MA 50$17.22
MA 200$16.76
MACDBullish
VolumeDecreasing
Fear & Greed Index88.98
Valuation
Fair Value$1.80
Target Price$24.24
Upside/Downside37.02%
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.83
Volatility26.61%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.